GBT provides regulatory and pipeline updates in sickle cell disease

Global Blood Therapeutics

22 July 2021 - Submits supplemental new drug application to the U.S. FDA for Oxbryta (voxelotor) in children with SCD ages 4 to 11.

Global Blood Therapeutics today announced updates across several of its development programs in sickle cell disease. 

The company has submitted a supplemental new drug application to the U.S. FDA seeking accelerated approval for Oxbryta (voxelotor) for the treatment of sickle cell disease in children ages 4 to 11 years, together with a related separate new drug application required to seek approval for a paediatric weight-based formulation of Oxbryta.

Read Global Blood Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Dossier